Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

BACKGROUND: Migraine pain relief is reported by more than 50% of patients who receive low dose (3 mg) of sumatriptan. Currently, there is no two-step autoinjector of low-dose sumatriptan available on the market for acute migraine treatment. To fulfill this need, a fully assembled, single-dose, subcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Brand-Schieber, Elimor, Munjal, Sagar, Kumar, Rajesh, Andre, Anthony D, Valladao, Will, Ramirez, Margarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892851/
https://www.ncbi.nlm.nih.gov/pubmed/27313479
http://dx.doi.org/10.2147/MDER.S105899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892851/
https://www.ncbi.nlm.nih.gov/pubmed/27313479
http://dx.doi.org/10.2147/MDER.S105899

Ejemplares similares